Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis-Reference-Cited by-同舟云学术

Efficacy of Crushed Delayed-Release Posaconazole Tablets in Rhino-Orbito-Cerebral Mucormycosis

Published:2022-12-20 Issue:12 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Manesh Abi¹^ORCID,Devasagayam Emily¹,Bhanuprasad Kundakarla¹,Mathew Sumith K.²^ORCID,Karthik Rajiv¹,Mathew Binu S.²,Varghese George M.¹

Affiliation:

1. Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India

2. Department of Clinical Pharmacology, Christian Medical College, Vellore, Tamil Nadu, India

Abstract

A significant proportion of patients with Rhino-orbito-cerebral mucormycosis (ROCM) develop oroantral fistulas. Due to the unclear efficacy of crushed delayed-release posaconazole tablets (DRPT) via nasogastric tube in this group of patients, clinicians often use inferior alternatives like posaconazole suspension. In this prospective study, we report good plasma concentrations (median, 2,639 ng/mL; interquartile range [IQR], 1,690 to 3,575 ng/mL; and range, 1,004 to 4,835ng/mL) and complete cure and survival at 3 and 6 months in 19 such patients.

Funder

Christian Medical College, Vellore

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01085-22

Reference14 articles.

1. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

2. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

3. Pharmacokinetics and Pharmacodynamics of Posaconazole